



EXPRESS MAIL NO. EV449556744US

04-05-04

TRANSMITTAL FORM (To be used for all correspondence after initial filing)	Application Number	10/648,780
	Filing Date	August 26, 2003
	First Named Inventor	Alexander Gaiger
	Art Unit	1632
	Examiner Name	
	Attorney Docket No.	210121.465C12

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 <input checked="" type="checkbox"/> 100 Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Individual Name	Julie A. Urvater, Ph.D., Patent Agent Reg. No. 50,461	Customer Number 00500
Signature		
Date	April 2, 2004	

VIA EXPRESS MAIL

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 470246

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Alexander Gaiger et al.
 Application No. : 10/648,780
 Filed : August 26, 2003
 For : COMPOSITIONS AND METHODS FOR WT1 SPECIFIC
 IMMUNOTHERAPY

Art Unit : 1632
 Docket No. : 210121.465C12
 Date : April 2, 2004

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Forms PTO-1449. This application is a continuation and relies, under 35 U.S.C. § 120, on the earlier filing date of prior application USAN 10/195,835, filed on July 12, 2002; which is a continuation-in-part of USAN 10/125,635, filed on April 16, 2002; which is a continuation-in-part of USAN 10/002,603, filed October 30, 2001; which is a continuation-in-part of USAN 09/938,864, filed August 24, 2001; which is a continuation-in-part of USAN 09/785,019, filed February 15, 2001; which is a continuation-in-part of USAN 09/685,830, filed October 9, 2000; which is a continuation-in-part of USAN 09/684,361, filed October 6, 2000; which is a continuation-in-part of USAN 09/276,484, filed March 25, 1999; which is a continuation in part of USAN 09/164,223, filed September 30, 1998. The references listed on pages 1-14 of the attached Forms PTO-1449 were submitted to and/or cited by the Office in these prior applications and, therefore, are not required to be provided in the present application. If the Examiner wishes, copies will be provided upon request. However, the references (exclusion of U.S. Patents) listed on pages 15-23 of Forms PTO-1449 are submitted herewith.

Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Applicants note that reference OI (JP 11-89596), submitted herewith, is written in Japanese. Accordingly, the Examiners attention is respectfully directed to references UI-UM, which present English abstracts and the relevant nucleotide sequences.

Applicants note that reference OJ (JP 11-89599), submitted herewith, is written in Japanese. Accordingly, the Examiners attention is respectfully directed to references UN and VC-VH, which present English abstracts and the relevant nucleotide sequences.

Applicants note that reference OK (WO 96/38176), submitted herewith, is written in Japanese. Accordingly, the Examiners attention is respectfully directed to references QM, QN and RC-RM, which present English abstracts and the relevant nucleotide sequences.

Applicants note that reference OL (WO 99/03506), submitted herewith, is written in Japanese. Accordingly, the Examiners attention is respectfully directed to references TD-TN and UC-UH, which present English abstracts and the relevant nucleotide sequences.


Applicants note that reference OM (WO 00/06602) is written in Japanese. Accordingly, the Examiners attention is respectfully directed to references VI-VN, WC and WD which present English abstracts and the relevant nucleotide sequences.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Commissioner is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC


Julie A. Urvater, Ph.D., Patent Agent
Registration No. 50,461

JAU:ljt

Enclosures:

Postcard

Form PTO/SB/21

Form PTO-1449 (23 sheets)

Cited References (100)

701 Fifth Avenue, Suite 6300

Seattle, Washington 98104-7092

Phone: (206) 622-4900

Fax: (206) 682-6031

V470257

APR 02 2004

FORM PTO-1445
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.465C12APPLICATION NO.
10/648,780

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Alexander Gaiger et al.FILING DATE
August 26, 2003GROUP ART UNIT
1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,350,840	09/27/94	Call et al.	536	23.1	
	AB	5,693,522	12/02/97	Chada et al.	435	2.402	
	AC	6,096,313	08/01/00	Jäger et al.	424	184.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AD	WO 00/18795	04/06/00	WIPO		
	AE	WO99/58135	11/18/99	PCT		
	AF	WO95/29995	11/09/95	PCT		
	AG	WO95/06725	03/09/95	PCT		
	AH	WO 94/21287	09/29/94	WIPO		
	AI	WO 95/29995	11/09/95	WIPO		
	AJ	WO 91/07509	05/30/91	PCT		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AK	Aaronson and Todaro, "Development of 3T3-like lines from Balb/c mouse embryo cultures: transformation susceptibility to SV40," <i>J. Cell. Physiol.</i> 72(2):141-148, October 1968.
	AL	Adachi et al., "Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1)," <i>Oncogene</i> 13: 2197-2203, 1996.
	AM	Algar et al., "A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines," <i>Oncogene</i> 12: 1005-1014, 1996.
	AN	Altman et al., "Phenotypic analysis of antigen-specific T lymphocytes," <i>Science</i> 274:94-96, October 4, 1996.
	AO	Appel, R.D. et al., "A new generation of information retrieval tools for biologists: the example of the ExPASy WWW server," <i>Trends in Biochemical Sciences</i> 19(6): 258-260, June 1994.
	AP	Armstrong et al., "The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo," <i>Mechanisms of Development</i> 40: 85-97, 1992.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	BB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	BC	Bellantuono et al., "Selective elimination of leukemic progenitors by allorestricted CTL specific for WILMS Tumor Antigen-1 (WT-1)," <i>Blood</i> , 94(10):532A-533A, November 15, 1999.					
	BD	Bergmann et al., "High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome," <i>Blood</i> 90(3): 1217-1225, 1997.					
	BE	Bergmann et al., "Wilms Tumor Gene Expression in Acute Myeloid Leukemias," <i>Leukemia and Lymphoma</i> 25: 435-443, 1997.					
	BF	Blaudeck, N. et al., "Specificity of Signal Peptide Recognition in Tat-Dependent Bacterial Protein Translocation," <i>Journal of Bacteriology</i> 183(2): 604-610, January 2001.					
	BG	Boon, T., "Tumor Antigens Recognized By Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy," <i>Int. J. Cancer</i> 54: 177-180, 1993.					
	BH	Brenner et al., "RNA polymerase chain reaction detects different levels of four alternatively spliced <i>WT1</i> transcripts in Wilms' tumors," <i>Oncogene</i> 7: 1431-1433, 1992.					
	BI	Brieger et al., "The Expression of the Wilms' Tumor Gene in Acute Myelocytic Leukemias as Possible Marker for Leukemic Blast Cells," <i>Leukemia</i> 8(12): 2138-2143, 1994.					
	BJ	Brieger et al., "The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR," <i>Annals of Oncology</i> 6: 811-816, 1995.					
	BK	Buckler et al., "Isolation, Characterization, and Expression of the Murine Wilms' Tumor Gene (WT1) During Kidney Development," <i>Molecular and Cellular Biology</i> 11: 1707-1712, 1991.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	CB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	CC	Call et al., "Isolation and Characterization of a Zinc Finger Polypeptide Gene at the Human Chromosome 11 Wilms' Tumor Locus," <i>Cell</i> 60: 509-520, 1990.					
	CD	Carapeti et al., "Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia," <i>Eur. J. Haematol.</i> 58: 346-349, 1997.					
	CE	Charles et al., "Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: an immunohistochemical study," <i>J. Clin. Pathol.: Mol. Pathol.</i> 50: 138-144, 1997.					
	CF	Charles et al., "Immunohistochemical detection of the Wilms' tumour gene WT1 in desmoplastic small round cell tumour," <i>Histopathology</i> 30: 312-314, 1997.					
	CG	Chen et al., "T-cells for tumor therapy can be obtained from antigen-loaded sponge implants," <i>Cancer Research</i> 54(4):1065-1070, February 15, 1994.					
	CH	Chesebro et al., "Characterization of Ia8 antigen, THY-1.2 antigen, complement receptors, and virus production in a group of murine virus-induced leukemia cell lines," <i>The Journal of Immunology</i> 117(4):1267-1274, October 1976.					
	CI	Crawford et al., "Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes," <i>Immunity</i> 8:675-682, June 1998.					
	CJ	De Bruijn et al., "Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses," <i>Eur J Immunol</i> 21(12):2963-2970, December 1991.					
	CK	Deavin et al., "Statistical comparison of established T-cell epitope predictors against a large database of human and murine antigens," <i>Molecular Immunology</i> , 33(2):145-155, 1996.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	DB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	DC	Drummond et al., "Repression of the Insulin-Like Growth Factor Gene by the Wilms Tumor Suppressor WT1," <i>Science</i> 257: 674-677, 1992.					
	DD	Feller and de la Cruz, "Tsites (Version 1.1) A computer program to determine T cell epitopes using four predictive algorithms," <i>Nature</i> 349: 720-721, 1991.					
	DE	Foster et al., "Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model," <i>Cancer Research</i> 57(16):3325-3330, August 15, 1997.					
	DF	Frazier et al., "Expression of the Tumor Suppressor Gene WT1 in Both Human and Mouse Bone Marrow," <i>Blood</i> 86: 4704-4706, 1995 (letter).					
	DG	Gaiger et al., "Immunity to WT1 in animal models and leukemia pateints," <i>Blood</i> , 94(10):78, November 15, 1999.					
	DH	Gaiger et al., "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," <i>Blood</i> 96(4):1480-1489, August 15, 2000.					
	DI	Gaiger et al., "WT1: A new leukemia and cancer antigen A," <i>Proceedings of the Annual Meeting of the American Association for Cancer Research</i> , 40:424, 1999.					
	DJ	Gillis and Smith, "Long term culture of tumour-specific cytotoxic T cells," <i>Nature</i> 268:154-156, July 14, 1977.					
	DK	Glynn et al., "Cross-resistance to the transplantation of syngeneic friend, moloney, and rauscher virus-induced tumors," <i>Cancer Research</i> 28(3):434-439, March 1968.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	EB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	EC	Goodyer et al., "Repression of the retinoic acid receptor- α gene by the Wilms' tumor suppressor gene product, wt1," <i>Oncogene 10</i> : 1125-1129, 1995.					
	ED	Haber et al., "A dominant mutation in the Wilms tumor gene <i>WT1</i> cooperates with the viral oncogene <i>E1A</i> in transformation of primary kidney cells," <i>Proc. Natl. Acad. Sci. USA 89</i> : 6010-6014, 1992.					
	EE	Haber et al., "Alternative splicing and genomic structure of the Wilms tumor gene <i>WT1</i> ," <i>Proc. Natl. Acad. Sci. USA 88</i> : 9618-9622, 1991.					
	EF	Haber et al., "An Internal Deletion within an 11p13 Zinc Finger Gene Contributes to the Development of Wilms' Tumor," <i>Cell 61</i> : 1257-1269, 1990.					
	EG	Hamilton et al., "High affinity binding sites for the Wilms' tumour suppressor protein WT1," <i>Nucleic Acids Research 23</i> (2): 277-284, 1995.					
	EH	Harrington et al., "Inhibition of Colony-stimulating Factor-1 Promoter Activity by the Product of the Wilms' Tumor Locus," <i>The Journal Of Biological Chemistry 268</i> (28): 21271-21275, 1993.					
	EI	Harrington et al., "Inhibition of Colony-stimulating Factor-1 Promoter Activity by the Product of the Wilms' Tumor Locus," <i>The Journal Of Biological Chemistry 268</i> (28): 21271-21275, 1993.					
	EJ	Horibata and Harris, "Mouse myelomas and lymphomas in culture," <i>Experimental Cell Research 60</i> : 61-77, 1970.					
	EK	Huang et al., "Tissue, Developmental, and Tumor-Specific Expression of Divergent Transcripts in Wilms Tumor," <i>Science 250</i> : 991-994, 1990.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	FB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	FC	Inoue et al., "Aberrant Overexpression of the Wilms Tumor Gene (WT1) in Human Leukemia," <i>Blood</i> 89(4): 1405-1412, 1997.					
	FD	Inoue et al., "Long-Term Follow-Up of Minimal Residual Disease in Leukemia Patients by Monitoring WT1 (Wilms Tumor Gene) Expression Levels," <i>Blood</i> 88: 2267-2278, 1996.					
	FE	Inoue et al., "Wilms' Tumor Gene (WT1) Competes With Differentiation-Inducing Signal in Hematopoietic Progenitor Cells," <i>Blood</i> 91(8): 2969-2976, 1998.					
	FF	Inoue et al., "WT1 as a New Prognostic Factor and a New Marker for the Detection of Minimal Residual Disease in Acute Leukemia," <i>Blood</i> 84: 3071-3079, 1994.					
	FG	King-Underwood and Pritchard-Jones, "Wilms' Tumor (WT1) Gene Mutations Occur Mainly in Acute Myeloid Leukemia and May Confer Drug Resistance," <i>Blood</i> 91(8): 2961-2968, 1998.					
	FH	King-Underwood et al., "Mutations in the Wilms' Tumor Gene WT1 in Leukemias," <i>Blood</i> 91: 2961-2968, 1998.					
	FI	Kreidberg et al., "WT-1 Is Required for Early Kidney Development," <i>Cell</i> 74: 679-691, 1993.					
	FJ	Kudoh et al., "Constitutive expression of the Wilms tumor suppressor gene WT1 in F9 embryonal carcinoma cells induces apoptotic cell death in response to retinoic acid," <i>Oncogene</i> 13: 1431-1439, 1996.					
	FK	Kudoh et al., "G ₁ phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes," <i>Proc. Natl. Acad. Sci. USA</i> 92: 4517-4521, 1995.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	GB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	GC	Kwok and Higuchi, "Avoiding false positives with PCR," <i>Nature</i> 339:237-238, May 18, 1989.					
	GD	Larsson et al., "Subnuclear Localization of WT1 in Splicing or Transcription Factor Domains Is Regulated by Alternative Splicing," <i>Cell</i> 81: 391-401, 1995.					
	GE	Ljunggren et al., "Empty MHC class I molecules come out in the cold," <i>Nature</i> 346:476-480, August 2, 1990.					
	GF	Lozzio and Lozzio, "Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome," <i>Blood</i> 45(3):321-334, March 1975.					
	GG	Luo et al., "The tumor suppressor gene WT1 inhibits <i>ras</i> -mediated transformation," <i>Oncogene</i> 11: 743-750, 1995.					
	GH	Madden et al., "Transcriptional Repression Mediated by the WT1 Wilms Tumor Gene Product," <i>Science</i> 253: 1550-1552, 1991.					
	GI	Maurer et al., "The Wilms' tumor gene is expressed in a subset of CD34 progenitors and downregulated early in the course of differentiation in vitro," <i>Experimental Hematology</i> 25: 945-950, 1997.					
	GJ	Menke et al., "Wilms' Tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells," <i>Oncogene</i> 12: 537-546, 1996.					
	GK	Menssen et al., "Detection By Monoclonal Antibodies Of The Wilms' Tumor (WT1) Nuclear Protein In Patients With Acute Leukemia," <i>Int. J. Cancer</i> 70: 518-523, 1997.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	HB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	HC	Menssen et al., "Presence of Wilms' tumor gene (<i>wt1</i>) transcripts and the WT1 nuclear protein in the majority of human acute leukemias," <i>Leukemia</i> 9: 1060-1067, 1995.					
	HD	Menssen et al., "Wilms' Tumor Gene Expression in Human CD34 Hematopoietic Progenitors During Fetal Development and Early Clonogenic Growth," <i>Blood</i> 89(9): 3486-3487, 1997 (letter).					
	HE	Miwa et al., "Expression of the Wilms' Tumor Gene (WT1) in Human Leukemias," <i>Leukemia</i> 6(5): 405-409, 1992.					
	HF	Miyagi et al., "Expression of the Candidate Wilms' Tumor Gene, <i>WT1</i> , in Human Leukemia Cells," <i>Leukemia</i> 7(7): 970-977, 1993.					
	HG	Morris et al., "Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus," <i>Oncogene</i> 6: 2339-2348, 1991.					
	HH	Mundlos et al., "Nuclear localization of the protein encoded by the Wilms' tumor gene <i>WT1</i> in embryonic and adult tissues," <i>Development</i> 119: 1329-1341, 1993.					
	HI	Murata et al., "The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells," <i>FEBS Letters</i> 409: 41-45, 1997.					
	HJ	Nakagama et al., "Sequence and Structural Requirements for High-Affinity DNA Binding by the WT1 Gene Product," <i>Molecular and Cellular Biology</i> 15(3): 1489-1498, 1995.					
	HK	Nichols et al., "WT1 Induces Expression of Insulin-like Growth Factor 2 in Wilms' Tumor Cells," <i>Cancer Research</i> 55: 4540-4543, 1995.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	IA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	IB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	IC		Ogawa et al., "Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogeneic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay," <i>Bone Marrow Transplantation</i> 21: 525-527, 1998.				
	ID		Old et al., "Antigenic properties of chemically induced tumors," <i>Annals of the New York Academy of Sciences</i> 101:80-107, November 20, 1962.				
	IE		Osaka et al., "WT1 Contributes To Leukemogenesis: Expression Patterns In 7,12-Dimethylbenz[a]Anthracene (DMBA)-Induced Leukemia," <i>International Journal of Cancer</i> 72: 696-699, 1997.				
	IF		Parker et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>Journal of Immunology</i> 152: 163-175, 1994.				
	IG		Parker, K.C. et al, "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>Journal of Immunology</i> 152(1): 163-175, January 1994.				
	IH		Patek et al., "Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis," <i>Nature</i> 276:510-511, November 30, 1978.				
	II		Patmasiriwat et al., "Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities," <i>Leukemia</i> 10: 1127-1133, 1996.				
	IJ		Peitsch, M.C., "ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling," <i>Biochemical Society Transactions</i> 24(1): 274-279, February 1996.				
	IK		Pelletier et al., "Expression of the Wilms' tumor gene WT1 in the murine urogenital system," <i>Genes & Development</i> 5: 1345-1356, 1991.				
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	JA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	JB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	JC	Pelletier et al., "Germline Mutations in the Wilms' Tumor Suppressor Gene Are Associated with Abnormal Urogenital Development in Denys-Drash Syndrome," <i>Cell</i> 67: 437-447, 1991.					
	JD	Phelan et al., "Wilms' Tumor Gene, <i>WT1</i> , mRNA Is Down-regulated during Induction of Erythroid and Megakaryocytic Differentiation of K562 Cells," <i>Cell Growth & Differentiation</i> 5: 677-686, 1994.					
	JE	Pogue et al., "Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and <i>in vitro</i> immunogenicity," <i>Proc. Natl. Acad. Sci. USA</i> 92: 8166-8170, 1995.					
	JF	Pritchard-Jones et al., "The candidate Wilms' tumour gene is involved in genitourinary development," <i>Nature</i> 346: 194-197, 1990.					
	JG	Pritchard-Jones et al., "The Wilms tumour (<i>WT1</i>) gene is mutated in a secondary leukaemia in a WAGR patient," <i>Human Molecular Genetics</i> 3(9): 1633-1637, 1994.					
	JH	Rackley et al., "Expression of the Wilms' Tumor Suppressor Gene <i>WT1</i> during Mouse Embryogenesis," <i>Cell Growth & Differentiation</i> 4: 1023-1031, 1993.					
	JI	Ramani and Cowell, "The Expression Pattern Of Wilms' Tumour Gene (<i>WT1</i>) Product In Normal Tissues And Paediatric Renal Tumours," <i>Journal Of Pathology</i> 179: 162-168, 1996.					
	JJ	Rammensee, H. et al., "SYFPEITHI: database for MHC ligands and peptide motifs," <i>Immunogenetics</i> 50(3-4): 213-219, November 1999.					
	JK	Rauscher et al., "Binding of the Wilms' Tumor Locus Zinc Finger Protein to the EGR-1 Consensus Sequence," <i>Science</i> 250: 1259-1262, 1990.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	KA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	KB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	KC	Rauscher et al., "Characterization of monoclonal antibodies directed to the amino-terminus of the WT1, Wilms' tumor suppressor," <i>Hybridoma</i> , 17(2):191-198, April 1998.					
	KD	Rauscher, "The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor," <i>FASEB J.</i> 7: 896-903, 1993.					
	KE	Reddy et al., "WT1-mediated Transcriptional Activation Is Inhibited by Dominant Negative Mutant Proteins," <i>The Journal Of Biological Chemistry</i> 270(18): 10878-10884, 1995.					
	KF	Rothbard and Taylor, "A sequence pattern common to T cell epitopes," <i>EMBO Journal</i> , 7(1):93-100, 1988.					
	KG	Rupprecht et al., "The Wilms' Tumor Suppressor Gene WT1 Is Negatively Autoregulated," <i>The Journal Of Biological Chemistry</i> 269(8): 6198-6206, 1994.					
	KH	Sadovnikova et al., "Generation of human tumor-reactive cytotoxic T-cells against peptides presented by non-self HLA class I molecules," <i>Eur.J. Immunol.</i> , 28:193-200, 1998.					
	KI	Santini, Claire-Lise et al., "Translocation of Jellyfish Green Fluorescent Protein via the Tat System of <i>Escherichia coli</i> and Change of Its Periplasmic Localization in Response to Osmotic Up-shock," <i>Journal of Biological Chemistry</i> 276(11): 8159-8164, March 16, 2001.					
	KJ	Schmid et al., "Prognostic significance of WT1 gene expression at diagnosis in adult <i>de novo</i> acute myeloid leukemia," <i>Leukemia</i> 11: 639-643, 1997.					
	KK	Sekiya et al., "Downregulation of Wilms' Tumor Gene (wt1) During Myelomonocytic Differentiation in HL60 Cells," <i>Blood</i> 83(7): 1876-1882, 1994.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	LA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO	
	LB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	LC	Sharma et al., "Molecular Cloning of Rat Wilms' Tumor Complementary DNA and a Study of Messenger RNA Expression in the Urogenital System and the Brain," <i>Cancer Research</i> 52: 6407-6412, 1992.					
	LD	Silberstein et al., "Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer," <i>Proc. Natl. Acad. Sci. USA</i> 94: 8132-8137, 1997.					
	LE	Skeiky et al., "Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis," <i>Infection and Immunity</i> 67(8):3998-4007, August 1999.					
	LF	Slavin and Strober, "Spontaneous murine B-cell leukaemia," <i>Nature</i> 272:624-626, April 13, 1978.					
	LG	Svedberg et al., "Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program," <i>Oncogene</i> 15: 1-8, 1997.					
	LH	Tadokoro et al., "Genomic Organization of the Human WT1 Gene," <i>Jpn. J. Cancer Res.</i> 83: 1198-1203, 1992.					
	LI	Tadokoro et al., "Intragenic homozygous deletion of the <i>WT1</i> gene in Wilms' tumor," <i>Oncogene</i> 7: 1215-1221, 1992.					
	LJ	Tadokoro et al., "PCR Detection of 9 Polymorphisms in the WT1 Gene," <i>Human Molecular Genetics</i> 2(12): 2205-2206, 1993.					
	LK	Tadokoro et al., "TaqI RFLPs at the Wilms' tumor gene (WT1)," <i>Nucleic Acids Research</i> 19(9): 2514, 1991.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	MA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	MB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	MC	Telerman et al., "Identification of the cellular protein encoded by the human Wilms' tumor (<i>WT1</i>) gene," <i>Oncogene 7</i> : 2545-2548, 1992.					
	MD	Toes et al., "Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts," <i>Int. J. Cancer</i> , 66:686-691, 1996.					
	ME	Tsurutani et al., "cDNA cloning and developmental expression of the porcine homologue of <i>WT1</i> ," <i>Gene 211</i> (2): 215-220, 1998.					
	MF	Wang et al., "A second transcriptionally active DNA-binding site for the Wilms tumor gene product, <i>WT1</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 90: 8896-8900, 1993.					
	MG	Wang et al., "The Wilms' Tumor Gene Product <i>WT1</i> Activates or Suppresses Transcription through Separate Functional Domains," <i>The Journal Of Biological Chemistry</i> 268(13): 9172-9175, 1993.					
	MH	Wang et al., "The Wilms' Tumor Gene Product, <i>WT1</i> , Represses Transcription of the Platelet-derived Growth Factor A-chain Gene," <i>The Journal Of Biological Chemistry</i> 267(31): 21999-22002, 1992.					
	MI	Wang et al., " <i>WT1</i> , the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein," <i>Oncogene 10</i> (6): 1243-1247, 1995.					
	MJ	Watson et al., "Leukemia viruses associated with mouse myeloma cells," <i>Proceeding of the National Academy of Sciences</i> 66(2):344-351, June 1970.					
	MK	Werner et al., "Inhibition of Cellular Proliferation by the Wilms' Tumor Suppressor <i>WT1</i> Is Associated with Suppression of Insulin-Like Growth Factor I Receptor Gene Expression," <i>Molecular and Cellular Biology</i> 15: 3516-3522, 1995.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	NA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	NB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	NC	Wu et al., "GATA-1 Transactivates the WT1 Hematopoietic Specific Enhancer," <i>The Journal Of Biological Chemistry</i> 270(11): 5944-5949, 1995.					
	ND	Wu, L.F. et al., "Bacterial Twin-Arginine Signal Peptide-Dependent Protein Translocation Pathway: Evolution and Mechanism," <i>J. Mol. Microbiol. Biotechnol.</i> 2(2): 179-189, April 2000.					
	NE	Yamagami et al., "Growth Inhibition of Human Leukemic Cells by WT1 (Wilms Tumor Gene) Antisense Oligodeoxynucleotides: Implications for the Involvement of WT1 in Leukemogenesis," <i>Blood</i> 87(7): 2878-2884, 1996.					
	NF	Werner et al., "Inhibition of Cellular Proliferation by the Wilms' Tumor Suppressor WT1 Is Associated with Suppression of Insulin-Like Growth Factor I Receptor Gene Expression," <i>Molecular and Cellular Biology</i> 15: 3516-3522, 1995.					
	NG						
	NH						
	NI						
	NJ						
	NK						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	OA	5,633,142	05/27/97	Herlyn et al.	435	7.23	
	OB	5,670,317	09/23/97	Ladanyi et al.	435	6	
	OC	5,726,288	03/10/98	Call et al.	530	350	
	OD	6,034,235	03/07/00	Sugiyama et al.	536	24.5	
	OE	6,277,832	08/21/01	Sugiyama et al.	514	44	
	OF	6,316,599 B1	11/13/01	Call et al.	530	387.7	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	OG	EP 1004319 A1	05/31/00	EPO			
	OH	EP 1103564 A1	05/30/01	EPO			
	OI	JP 11-89596 A	04/06/99	Japan			X
	OJ	JP 11-89599 A	04/06/99	Japan			X
	OK	WO 96/38176	12/05/96	WIPO			X
	OL	WO 99/03506	01/28/99	WIPO			X
	OM	WO 00/06602	02/10/00	WIPO			X
	ON	WO 01/60970	08/23/01	WIPO			
	OO	WO 01/94629	12/13/01	WIPO			
	OP	WO 02/00677	01/03/02	WIPO			
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	OQ	Oka, Y. et al., "Wilms Tumor Gene Peptide-Based Immunotherapy for Patients with Overt Leukemia from Myelodysplastic Syndrome (MDS) or MDS with Myelofibrosis," <i>International Journal of Hematology</i> 78: 56-61, 2003.					
	OR	GenBank Database, Accession No. A39692, February 16, 1997.					
	OS	GenBank Database, Accession No. AAA36810, June 15, 1990.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	PA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	PB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	PC	GenBank Database, Accession No. AAA62825, October 27, 1994.					
	PD	GenBank Database, Accession No. AAB33427, May 12, 1995.					
	PE	GenBank Database, Accession No. AAB33443, July 11, 1995.					
	PF	GenBank Database, Accession No. AAC60039, November 8, 1996.					
	PG	GenBank Database, Accession No. BAA94794, April 21, 2000.					
	PH	GenBank Database, Accession No. CAA35956, May 29, 1991.					
	PI	GenBank Database, Accession No. CAA43819, December 3, 1993.					
	PJ	GenBank Database, Accession No. CAA59736, February 13, 1996.					
	PK	GenBank Database, Accession No. I51960, November 5, 1999.					
	PL	GenBank Database, Accession No. M30393, June 15, 1990.					
	PM	GenBank Database, Accession No. NM_000378, November 5, 2000.					
	PN	GenBank Database, Accession No. NM_024424, March 20, 2001.					
EXAMINE				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	QA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	QB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	QC	GenBank Database, Accession No. NM_024426, March 20, 2001.					
	QD	GenBank Database, Accession No. NP_000369, November 5, 2000.					
	QF	GenBank Database, Accession No. NP_077742, March 20, 2001.					
	QF	GenBank Database, Accession No. NP_077743, March 20, 2001.					
	QG	GenBank Database, Accession No. NP_077744, March 20, 2001.					
	QH	GenBank Database, Accession No. NP_113722, April 6, 2003.					
	QI	GenBank Database, Accession No. O62651, November 1, 1998.					
	QJ	GenBank Database, Accession No. P50902, October 1, 1996.					
	QK	GenBank Database, Accession No. S75264, July 11, 1995.					
	QL	GenBank Database, Accession No. X51630, May 29, 1991.					
	QM	Geneseq Database, Accession No. AAT45130, August 19, 1997.					
	QN	Geneseq Database, Accession No. AAT45131, August 20, 1997.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	RA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	RB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	RC	Geneseq Database, Accession No. AAT45132, August 20, 1997.					
	RD	Geneseq Database, Accession No. AAT45133, August 20, 1997.					
	RE	Geneseq Database, Accession No. AAT45134, August 20, 1997.					
	RF	Geneseq Database, Accession No. AAT45135, August 20, 1997.					
	RG	Geneseq Database, Accession No. AAT45136, August 20, 1997.					
	RH	Geneseq Database, Accession No. AAT45137, August 20, 1997.					
	RI	Geneseq Database, Accession No. AAT45138, August 20, 1997.					
	RJ	Geneseq Database, Accession No. AAT45139, August 20, 1997.					
	RK	Geneseq Database, Accession No. AAT45140, August 20, 1997.					
	RL	Geneseq Database, Accession No. AAT45141, August 20, 1997.					
	RM	Geneseq Database, Accession No. AAT45142, August 20, 1997.					
	RN	Geneseq Database, Accession No. AAT97855, March 9, 1998.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.465C12APPLICATION NO.
10/648,780**INFORMATION DISCLOSURE STATEMENT***(Use several sheets if necessary)*

APPLICANTS

Alexander Gaiger et al.

FILING DATE

August 26, 2003

GROUP ART UNIT

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	SA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	SB					

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	SC	Geneseq Database, Accession No. AAT97856, March 9, 1998.
	SD	Geneseq Database, Accession No. AAT97857, March 9, 1998.
	SE	Geneseq Database, Accession No. AAT97858, March 9, 1998.
	SF	Geneseq Database, Accession No. AAT97859, March 9, 1998.
	SG	Geneseq Database, Accession No. AAT97860, March 9, 1998.
	SH	Geneseq Database, Accession No. AAT97861, March 9, 1998.
	SI	Geneseq Database, Accession No. AAT97862, March 9, 1998.
	SJ	Geneseq Database, Accession No. AAT97863, March 9, 1998.
	SK	Geneseq Database, Accession No. AAT97864, March 9, 1998.
	SL	Geneseq Database, Accession No. AAT97865, March 9, 1998.
	SM	Geneseq Database, Accession No. AAT97866, March 9, 1998.
	SN	Geneseq Database, Accession No. AAT97867, March 9, 1998.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	TA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	TB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	TC	Geneseq Database, Accession No. AAT97868, March 9, 1998.					
	TD	Geneseq Database, Accession No. AAX15839, May 11, 1999.					
	TE	Geneseq Database, Accession No. AAX15840, May 11, 1999.					
	TF	Geneseq Database, Accession No. AAX15841, May 11, 1999.					
	TG	Geneseq Database, Accession No. AAX15842, May 11, 1999.					
	TH	Geneseq Database, Accession No. AAX15843, May 11, 1999.					
	TI	Geneseq Database, Accession No. AAX15844, May 11, 1999.					
	TJ	Geneseq Database, Accession No. AAX15845, May 11, 1999.					
	TK	Geneseq Database, Accession No. AAX15846, May 11, 1999.					
	TL	Geneseq Database, Accession No. AAX15847, May 11, 1999.					
	TM	Geneseq Database, Accession No. AAX15848, May 11, 1999.					
	TN	Geneseq Database, Accession No. AAX15849, May 11, 1999.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	UA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	UB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	UC	Geneseq Database, Accession No. AAX15850, May 11, 1999.					
	UD	Geneseq Database, Accession No. AAX15851, May 11, 1999.					
	UE	Geneseq Database, Accession No. AAX15852, May 11, 1999.					
	UF	Geneseq Database, Accession No. AAX15853, May 11, 1999.					
	UG	Geneseq Database, Accession No. AAX15854, May 11, 1999.					
	UH	Geneseq Database, Accession No. AAX15855, May 11, 1999.					
	UI	Geneseq Database, Accession No. AAX23927, June 25, 1999.					
	UJ	Geneseq Database, Accession No. AAX23928, June 25, 1999.					
	UK	Geneseq Database, Accession No. AAX23929, June 25, 1999.					
	UL	Geneseq Database, Accession No. AAX23930, June 25, 1999.					
	UM	Geneseq Database, Accession No. AAX23931, June 25, 1999.					
	UN	Geneseq Database, Accession No. AAX34315, July 6, 1999.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C12		APPLICATION NO. 10/648,780	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE August 26, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	VA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	VB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	VC	Geneseq Database, Accession No. AAX34316, July 6, 1999.					
	VD	Geneseq Database, Accession No. AAX34317, July 6, 1999.					
	VE	Geneseq Database, Accession No. AAX34318, July 6, 1999.					
	VF	Geneseq Database, Accession No. AAX34319, July 6, 1999.					
	VG	Geneseq Database, Accession No. AAX34320, July 6, 1999.					
	VH	Geneseq Database, Accession No. AAX34321, July 6, 1999.					
	VI	Geneseq Database, Accession No. AAY80196, May 24, 2000.					
	VJ	Geneseq Database, Accession No. AAY80197, May 24, 2000.					
	VK	Geneseq Database, Accession No. AAY80198, May 24, 2000.					
	VL	Geneseq Database, Accession No. AAY80199, May 24, 2000.					
	VM	Geneseq Database, Accession No. AAY80200, May 24, 2000.					
	VN	Geneseq Database, Accession No. AAY80201, May 24, 2000.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							


FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.465C12APPLICATION NO.
10/648,780**INFORMATION DISCLOSURE STATEMENT***(Use several sheets if necessary)*APPLICANTS
Alexander Gaiger et al.FILING DATE
August 26, 2003GROUP ART UNIT
1632**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	WA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	WB					

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	WC		Genseq Database, Accession No. AAY80202, May 24, 2000.
	WD		Genseq Database, Accession No. AAY80203, May 24, 2000.
	WE		Genseq Database, Accession No. ABP42234, August 22, 2002.
	WF		
	WG		
	WH		
	WI		
	WJ		
	WK		
	WL		
	WM		
	WN		

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).